The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today announced that it has awarded 11 grants with a total first-year value of approximately $17 million to establish the Centers for Research in Emerging...
Virology
Category
The Complexities of COVID-19 Immunity: Smithsonian Magazine
In a May 26 piece, Smithsonian Magazine reports on the interesting and challenging complexities of moving towards COVID-19 immunity. They note that antibodies fight disease and can also help as evidence of whether a person had a prior COVID-19 infection. The challenge...
ViiV Healthcare Halts Prevention Trial Early After Cabotegravir Dosed Every Two Months Shows Higher Efficacy Than Daily Standard of Care
ViiV Healthcare announced the HIV Prevention Trials Network (HPTN) 083 study will be stopped early following an interim analysis showing long-acting, injectable cabotegravir (CAB LA) administered every two months is 69% more effective than the current standard of...
Data from Patients with COVID-19 Complications Treated Gilead’s Remdesivir Published in The New England Journal of Medicine
Gilead announced results from a cohort analysis of 53 patients hospitalized with severe complications of COVID-19 who were treated with the investigational antiviral remdesivir on an individual compassionate use basis have been published in The New England Journal of...
Fort Detrick Researchers Ominously Prescient in their Analysis of a New & Dangerous Coronavirus
In 2018, two researchers with the United States Army Medical Research Institute of Infectious Disease at Fort Detrick put forth an ominous warning that coronavirus represents a highly pathogenic and dangerous virus that has emerged in human populations over the past...
Sanofi Pasteur Extends External Collaboration with mRNA-based Biotech to Target COVID-19 Vaccine
Sanofi Pasteur, the vaccines global business unit of Sanofi (NASDAQ: SNY), externalized COVID-19 vaccine research and developed inking an extension deal with Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company to develop a novel...
UK’s NIHR Government Injects £20 Million into COVID-19 R&D Including Clinical Trials
The government, via the National Institute for Health Research (NIHR) of the United Kingdom (UK), announced a £20 million infusion into six research studies focusing on new COVID-19 vaccines in a quest to establish the UK as a major scientific presence in leading the...
UC Irvine Initiates Participation in Worldwide NIAID-Sponsored Adaptive COVID-19 Clinical Trial Assessing Remdesivir (Gilead)
University of California, Irvine (UCI) joins other pathbreaking major academic centers serving as clinical investigative sites nationwide to test Gilead’s remdesivir, the novel antiviral drug developed as a treatment for the Ebola and Marburg virus. With UCI’s...
Innovative UNC-based Public-Private HIV Investigative Group Secures $20m & Continues its Leading ‘Induce & Reduce’ Strategy
University of North Carolina (UNC) Chapel Hill researchers and local industry scientists secured $20 million in the from of a research contract targeting a cure for HIV. The deal was executed between ViiV Healthcare and UNC at Chapel Hill to renew the unique,...
University of Adelaide-led Virus Research Team Introduces T-Cell based Zika Vaccine Advances
University of Adelaide affiliated researchers have made significant advances in developing a novel vaccine against Zika virus. The vaccine candidate could possibly lead to global eradication of the disease. A breakthrough, it is the first T-cell based investigational...
TEDDY Study Revealing Viruses in High Risk Children Linked to Type I Diabetes
The Environmental Determinants of Diabetes in the Young (TEDDY) study is the largest prospective observational cohort study of newborns with increased genetic risk for Type 1 diabetes (T1D). The TEDDY study operates in U.S. (Colorado, Georgia/Florida and Washington...